First-line treatment with targeted therapies plus chemotherapy offered overall response benefits in BRAF V600E-mutant ...

Patients with metastatic colorectal cancer (mCRC) harboring BRAF V600E mutations benefitted from first-line treatment with the targeted therapies encorafenib and cetuximab plus a mFOLFOX6 chemotherapy ...

Dr. Scott Kopetz discusses the BREAKWATER trial investigating Braftovi and Erbitux plus chemo in those with BRAF V600E+ ...

Pfizer Inc. (PFE) announced positive results from the Phase 3 BREAKWATER trial evaluating BRAFTOVI (encorafenib) in combination with ...

Patients with metastatic colorectal cancer (mCRC) harboring BRAF V600E mutations benefited from first-line treatment with the targeted therapies encorafenib and cetuximab plus a mFOLFOX6 chemotherapy ...

Pfizer Inc. (NYSE: PFE) today announced positive results from the Phase 3 BREAKWATER trial evaluating BRAFTOVI® (encorafenib) ...

Bowel cancer can start in the large bowel (colon cancer) or back passage (rectal cancer). It is also called colorectal cancer.. Your treatment depends on whether you have colon or rectal cancer. Your ...

Colon cancer symptoms in women include diarrhea, constipation, unintended weight loss, and bloody stools. While these are the same for anyone with colon cancer, symptoms in women may be misattributed ...

Patients with heavily pretreated microsatellite stable metastatic colorectal cancer (CRC) had survival benefits after using combinations based in immune checkpoint inhibitors. Older adults on ...